If your cancer has specific gene mutations and isn’t responding to certain hormone therapies,

LYNPARZA is a different kind of therapy for your unique type of metastatic prostate cancer.

Talk to your doctor about a test to see if LYNPARZA is right for you

Talk to your doctor about a test to see if LYNPARZA is right for you.

LYNPARZA IS
for men with HRR gene mutations whose prostate cancer has spread to other parts of the body, no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with enzalutamide or abiraterone. Your healthcare provider will perform a test to make sure LYNPARZA is right for you.

LYNPARZA is not a hormone therapy or chemotherapy. It’s an oral medication—two tablets, twice a day—that you can take with you wherever you go.

LYNPARZA tablets

Images do not represent the actual size of the tablets.

Knowing your HRR status could help you and your doctor decide on a treatment targeted to your unique cancer.

Testing is key to finding HRR gene mutations such as BRCA1, BRCA2, and ATM mutations, which were present in 28% of patients with this unique type of metastatic prostate cancer in a study. The presence of HRR gene mutations in your tumor may inform a treatment journey.

Mutations can be acquired or inherited. Testing could also show if people in your family might be at risk of developing cancer.

FOR MEN WITH BRCA1, BRCA2, OR ATM MUTATIONS AND mCRPC

LYNPARZA MAY GIVE YOU MORE TIME WITHOUT YOUR CANCER GETTING WORSE*

The data below are a subset of a larger study that tested a total of 387 men who had 1 or more of 15 HRR genetic tumor mutations and metastatic castration-resistant prostate cancer (mCRPC) after they were no longer responding to hormone therapies enzalutamide or abiraterone. The subset consisted of 245 men with BRCA1, BRCA2, or ATM gene mutations. 162 men took LYNPARZA 300 mg twice daily and 83 took hormone therapies enzalutamide or abiraterone.

2X *LYNPARZA more than doubled the median without cancer progressing or death compared to treatment with hormone therapies enzalutamide or abiraterone.

2X

*LYNPARZA more than doubled the median time without cancer progressing or death compared to treatment with hormone therapies enzalutamide or abiraterone.

MEDIAN TIME ON LYNPARZA

7.4 Months

MEDIAN TIME ON ENZALUTAMIDE OR ABIRATERONE

3.6 Months

56 out of 162 men did not have disease progression or death with LYNPARZA vs 15 out of 83 men on enzalutamide or abiraterone.

In addition to BRCA1, BRCA2, and ATM, other HRR genes included BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L. No patients were included who had mutations in 2 of the 15 pre-specified HRR genes: FANCL and RAD51C. Although patients with mutations in PPP2R2A were studied, LYNPARZA is not indicated for the treatment of patients with this gene mutation.

LYNPARZA MAY HELP PATIENTS LIVE LONGER COMPARED TO ENZALUTAMIDE OR ABIRATERONE

LYNPARZA lowered the risk of death by 31% compared to treatment with hormone therapies enzalutamide or abiraterone.

These data are a secondary conclusion, or result, of the overall study.

In this subset, 71 out of 162 patients treated with LYNPARZA were alive at the time of follow-up compared to 26 out of 83 treated with enzalutamide or abiraterone.

The median time of survival after the start of LYNPARZA was 19.1 months vs 14.7 months on enzalutamide or abiraterone.

LOWER RISK OF DEATH

31%

These data are a secondary conclusion, or result, of the overall study.

In this subset, 71 out of 162 patients treated with LYNPARZA were alive at the time of follow-up compared to 26 out of 83 treated with enzalutamide or abiraterone.

The median time of survival after the start of LYNPARZA was 19.1 months vs 14.7 months on enzalutamide or abiraterone.

MORE MEN ON LYNPARZA (33%) SAW THEIR TUMORS SHRINK VS 2% OF MEN ON ENZALUTAMIDE OR ABIRATERONE

PERCENTAGE OF MEN ON LYNPARZA

33%

VS

PERCENTAGE OF MEN ON ENZALUTAMIDE OR ABIRATERONE

2%

These data are a secondary conclusion, or result, of the overall study, and are based on 127 patients. 28 out of 84 men responded to LYNPARZA vs 1 out of 43 on enzalutamide or abiraterone.

PERCENTAGE OF MEN ON LYNPARZA

33%

VS

PERCENTAGE OF MEN ON ENZALUTAMIDE OR ABIRATERONE

2%

These data are a secondary conclusion, or result, of the overall study, and are based on 127 patients. 28 out of 84 men responded to LYNPARZA vs 1 out of 43 on enzalutamide or abiraterone.

FOR MEN WITH A VARIETY OF SELECT HRR GENE MUTATIONS,* INCLUDING BRCA1, BRCA2, AND ATM MUTATIONS

LYNPARZA MAY INCREASE THE TIME WITHOUT YOUR CANCER GETTING WORSE

THESE RESULTS WERE FROM MEN WITH A VARIETY OF SELECT HRR GENE MUTATIONS* —NOT JUST BRCA1, BRCA2 AND ATM

The data below are a secondary conclusion, or result, of the overall study, which tested a total of 387 men who had 1 or more of 15* HRR genetic tumor mutations and metastatic castration-resistant prostate cancer (mCRPC) after they were no longer responding to hormone therapies enzalutamide or abiraterone. 256 men took LYNPARZA 300 mg twice daily and 131 took hormone therapies enzalutamide or abiraterone.

LYNPARZA increased the median time without cancer progressing or death compared to treatment with hormone therapies enzalutamide or abiraterone.

MEDIAN TIME ON LYNPARZA

5.8 Months

MEDIAN TIME ON ENZALUTAMIDE OR ABIRATERONE

3.5 Months

76 out of 256 men did not have disease progression or death with LYNPARZA vs 32 out of 131 men on enzalutamide or abiraterone.

*In addition to BRCA1, BRCA2, and ATM, other HRR genes included BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L. No patients were included who had mutations in 2 of the 15 pre-specified HRR genes: FANCL and RAD51C. Although patients with mutations in PPP2R2A were studied, LYNPARZA is not indicated for the treatment of patients with this gene mutation.

Patient Support

AstraZeneca Access 360 logo

AstraZeneca Access 360TM

Helps you access the care you need

If your doctor has prescribed LYNPARZA, you may have questions. The AstraZeneca Access 360TM program can help. We can answer your questions about insurance coverage, out-of-pocket costs, and patient assistance programs. To learn more about the Access 360 program, please call 1-844-ASK-A360 (1-844-275-2360) Monday-Friday 8 AM-8 PM ET, or visit www.MyAccess360.com.

LYNPARZA $0 co-pay

AstraZeneca strives to make LYNPARZA affordable by targeting a $0 co-pay for all eligible patients

This is based on commercially insured patients. The average monthly cost for LYNPARZA may be greater than $0 for some patients.

LYNPARZA support hotline

Support Hotline

If you have any questions about LYNPARZA, speak with one of our specially trained nurses.
To speak with a nurse, call 1-800-770-8337.

How to take LYNPARZA

LYNPARZA can fit into your daily routine. You can take LYNPARZA with you wherever you go. It’s two tablets (150 mg each), taken by mouth in the morning and in the evening, with or without food, totaling four tablets each day (600 mg daily dose).

How to take LYNPARZA

2 TABLETS IN THE MORNING

+
How to take LYNPARZA

2 TABLETS IN THE EVENING

Take doses 12 hours apart with or without food.

Images do not represent the actual tablet size of the tablets.

If you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with LYNPARZA unless you have had a surgery to lower the amount of testosterone in your body (surgical castration).

Important things to keep in mind when taking LYNPARZA

  • You should take LYNPARZA exactly as your doctor tells you
  • Swallow the tablets whole—do not chew, crush, dissolve, or divide them
  • Take each dose about 12 hours apart, with or without food
  • Take LYNPARZA by mouth 2 times a day
  • Do not take more than 4 tablets a day
  • Do not change your dose or stop taking LYNPARZA unless your doctor tells you to. Your doctor may temporarily stop treatment with LYNPARZA or change your dose of LYNPARZA if you experience side effects

Foods to avoidAvoid grapefruit, grapefruit juice, Seville oranges and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

If you miss a doseTake your next dose at the usual scheduled time. Do not take an extra dose to make up for the one you missed.

If you take too muchCall your doctor or go to the nearest hospital emergency room right away.

Each treatment plan is unique and any questions you might have should be discussed with your doctor.

Downloadable resources

LYNPARZA patient information

Learn about how LYNPARZA works, data from clinical trials, side effects, and dosing information.

Downloadable resources icon

DOWNLOAD
Prostate Cancer Patient Brochure

Tips for managing your treatment

Learn more about the potential side effects of LYNPARZA and how you should work with your doctor to manage them.

Downloadable resources icon

DOWNLOAD
Tips for Managing Your Treatment Brochure

LYNPARZA caregivers

Our Caregiver Brochure provides useful tips and information. Learn more about the importance of looking after yourself as a caregiver.

Downloadable resources icon

DOWNLOAD
LYNPARZA Caregiver Brochure

My LYNPARZA support

Education and support may help make a meaningful difference.

Registration

Sign up forMy LYNPARZA Support Program

MyLYNPARZA is a support program that is unique to your treatment journey. We developed this program with one goal in mind: to be there for you and your loved ones.

*Required fields.

An error has occurred. Please make sure you have correctly filled out the highlighted fields.

 
 
 
 
 
 
 I am a patient taking LYNPARZA
 I care for someone taking LYNPARZA
 I would like to receive information in the future about relevant AstraZeneca products, programs, and services that may be of interest to me.
 I would like to receive the MyLYNPARZA treatment journal.
 1
 
 
 

By clicking SUBMIT, you are certifying that you or the individual you are signing up is 18 years or older and agrees to receive information from AstraZeneca about programs and services related to LYNPARZA.

We protect your information. AstraZeneca respects your personal health information. The information you provide may be used to send you health-related materials and to develop products, services, and programs. AstraZeneca, or third parties working on our behalf, will not sell or rent personal health information. If, in the future, you no longer want to receive health-related materials, call 1-800-236-9933. Please visit www.azprivacynotice.com to review our Privacy Notice.


THANKS FOR JOINING MYLYNPARZA

Your submission was successful.

WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

  • prostate cancer with certain inherited or acquired abnormal genes called homologous recombination repair (HRR genes). LYNPARZA is used when the cancer has spread to other parts of the body (metastatic), and no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with enzalutamide or abiraterone. Your healthcare provider will perform a test to make sure LYNPARZA is right for you

It is not known if LYNPARZA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.

Your healthcare provider will do blood tests to check your blood cell counts:

  • before treatment with LYNPARZA
  • every month during treatment with LYNPARZA
  • weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve

Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.

Blood clots (Venous Thromboembolic Events). Some people with prostate cancer who take LYNPARZA along with gonadotropin-releasing hormone (GnRH) analog therapy may develop a blood clot in a deep vein, usually in the leg (venous thrombosis) or a clot in the lung (pulmonary embolism). Tell your healthcare provider if you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you for these symptoms and may prescribe blood thinner medicine.

Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:

  • have lung or breathing problems
  • have kidney problems
  • are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with LYNPARZA
    • Males with female partners who are pregnant or able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 3 months after the last dose of LYNPARZA
    • Do not donate sperm during treatment with LYNPARZA and for 3 months after your final dose
  • are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.

How should I take LYNPARZA?

  • Take LYNPARZA tablets exactly as your healthcare provider tells you
  • Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to. Your healthcare provider may temporarily stop treatment with LYNPARZA or change your dose of LYNPARZA if you experience side effects
  • Your healthcare provider will decide how long you stay on treatment
  • Do not take more than 4 LYNPARZA tablets in 1 day. If you have any questions about LYNPARZA, talk to your healthcare provider or pharmacist
  • Take LYNPARZA by mouth 2 times a day
  • Each dose should be taken about 12 hours apart
  • Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets
  • Take LYNPARZA with or without food
  • If you are taking LYNPARZA for prostate cancer and you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with LYNPARZA unless you have had a surgery to lower the amount of testosterone in your body (surgical castration)
  • If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
  • If you take too much LYNPARZA, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?

Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

LYNPARZA may cause serious side effects (see above). The most common side effects of LYNPARZA are:

  • nausea or vomiting. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms
  • tiredness or weakness
  • low red blood cell counts
  • diarrhea
  • loss of appetite
  • headache
  • low white blood cell counts
  • changes in the way food tastes
  • cough
  • shortness of breath
  • dizziness
  • indigestion or heartburn
  • low platelet counts
  • upper stomach area (abdominal) pain

These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.

You may report side effects related to AstraZeneca products by clicking here. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088 .

Please click here for complete Prescribing Information, including Patient Information (Medication Guide).

IMPORTANT SAFETY INFORMATION

Read More

LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.